(Q46572104)

English

Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20).

scientific article published on 13 August 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/23942774

Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20). (English)

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/23942774

phase III clinical trial

0 references

0 references

0 references

metastatic melanoma

1 reference

based on heuristic

inferred from title

4

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/23942774

author name string

D McDermott

1

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/23942774

J Haanen

2

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/23942774

T-T Chen

3

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/23942774

S O'Day

5

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/23942774

MDX010-20 Investigators

6

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/23942774

publication date

13 August 2013

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/23942774

Annals of Oncology

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/23942774

24

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/23942774

2694-2698

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/23942774

10

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/23942774

Systematic review of medical treatment in melanoma: current status and future prospects.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT291

21 January 2018

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT291

21 January 2018

CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT291

21 January 2018

Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT291

21 January 2018

Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT291

21 January 2018

gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT291

21 January 2018

Long-term survival in patients with metastatic melanoma treated with DTIC or temozolomide

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT291

21 January 2018

Single dose of anti-CTLA-4 enhances CD8+ T-cell memory formation, function, and maintenance

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT291

21 January 2018

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT291

21 January 2018

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT291

21 January 2018

Management of immune-related adverse events and kinetics of response with ipilimumab

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT291

21 January 2018

Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT291

21 January 2018

Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT291

21 January 2018

Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT291

21 January 2018

Identifiers

10.1093/ANNONC/MDT291

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/23942774

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/23942774

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46572104&oldid=1404678218"